A recent study showed that ADAM17 is decreased by hypoxia and contributes to hypoxia-induced cisplatin resistance via the EGFR/PI3K/Akt pathway in HCC [23]. This evidence concerns the gene ADAM17 and hepatocellular carcinoma.